Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Molecules Engineered to Fight Alzheimer’s Disease and Other Neurodegenerative Disorders

By BiotechDaily International staff writers
Posted on 05 May 2014
Researchers have engineered a set of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer’s, Parkinson’s, and Huntington’s diseases.

These molecules are based on what NeuroPhage Pharmaceuticals, Inc. (Cambridge, MA, USA), the developer of the technology, calls a general amyloid interaction motif (GAIM), which recognizes a characteristic that is typical to many toxic, misfolded proteins, not only one type of misfolded protein. This approach provides a range of therapeutic targets, so that a number of pathologies, such as amyloid beta plaques, tau tangles and alpha-synuclein Lewy bodies, can all be tackled simultaneously with a single drug candidate.

Moreover, GAIM molecules have been shown to not only prevent the formation of new toxic protein aggregates but can also dissipate existing aggregates in the form of both soluble oligomers and insoluble fibers, such as plaques and tangles.

“The research published […] describes GAIM, NeuroPhage’s unique approach to treat diseases characterized by misfolded proteins. GAIM has the potential to provide a more robust response than previous therapies because it enables the simultaneous targeting of multiple pathologies within a single disease,” said Dr. Richard Fisher, chief scientific officer at NeuroPhage. The findings of this technology were published online April 22, 2014, in the Journal of Molecular Biology. “Symptoms of neurodegenerative diseases often appear well after the troublesome aggregates have begun to accumulate in the brain. By then, therapies that only target newly forming aggregates are likely to only slow the progression of the disease and are believed to be too late once the aggregates are formed,” said Dr. Gregory A. Petsko, a professor of neurology at Weill Cornell Medical College (New York, NY, USA) and a professor of biochemistry and chemistry, at Brandeis University (Waltham, MA, USA). “Therapies based on GAIM would represent a completely new paradigm in the treatment of many neurodegenerative diseases with their potential to ameliorate existing symptoms and prevent disease progression. The hope is this will eventually lead to a real treatment for Alzheimer’s disease, but for now, the science behind it is quite compelling.”

Researchers used a range of techniques, including X-ray fiber diffraction and nuclear magnetic resonance spectroscopy (NMRS), to demonstrate the activities of GAIM. They found that GAIM effectively binds to multiple types of misfolded proteins during their formation in such a way that prevents new toxic protein aggregates from forming. Furthermore, upon incubating GAIM with various misfolded proteins, the researchers observed that GAIM disrupted these assemblies of misfolded proteins by causing a conformational alteration in their structures. This structural change could enable the body’s natural disposal processes to recognize and clear the misfolded proteins, which in principle, would enable the brain to return to a more normal state. The capability to destabilize pre-existing aggregates of multiple types of misfolded proteins is unique in the field.

The discovery of GAIM has led to the creation of NeuroPhage’s lead candidate, NPT088, which is the GAIM motif fused to a portion of a human antibody. The outcome is a potential therapeutic that can be simply delivered to patients. NeuroPhage has gathered extensive preclinical data on this candidate, showing its effectiveness across disease models of Alzheimer’s, Parkinson’s and related diseases characterized by aggregation of the tau protein. NeuroPhage expects that NPT088 will be ready for human studies in late 2015.

“With recent advances in imaging agents for beta-amyloid and tau in Alzheimer’s disease, we believe we should be able to demonstrate clinical proof of mechanism in a phase 1b study with NPT088,” said Jonathan Solomon, CEO at NeuroPhage. “If successful, we would then have the opportunity to pursue many therapeutic options in several neurodegenerative diseases of protein aggregation.”

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental decline and dementia. NeuroPhage is initially developing candidates to treat Alzheimer’s and Parkinson’s disease, in which a number of different misfolded proteins accumulate, acting jointly to additionally intensify disease progression.

Related Links:

NeuroPhage Pharmaceuticals



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.